We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Genomic Test Aids in Determining Prostate Cancer Treatment Options

By LabMedica International staff writers
Posted on 06 Aug 2021
Print article
Real-world data support the clinical utility of the Decipher Prostate Biopsy Genomic Test for determining prostate cancer treatment options (Photo courtesy of Clinical Lab Products)
Real-world data support the clinical utility of the Decipher Prostate Biopsy Genomic Test for determining prostate cancer treatment options (Photo courtesy of Clinical Lab Products)
A clinical study has confirmed that a commercially available genomic test was useful for identifying which prostate cancer patients would benefit from more immediate and aggressive treatment.

Treatment of newly identified prostate cancer patients requires choosing between a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation treatment.

Investigators at the University of Michigan (Ann Arbor, USA) assessed the clinical utility of the Veracyte (San Francisco, CA, USA) Decipher Biopsy test for identify patients who are at high risk of cancer progression and require a more aggressive treatment approach.

The Decipher Prostate Genomic Test was developed from a large cohort of metastatic and non-metastatic prostate cancer patients treated at the Mayo Clinic. This whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.

In the current study, 855 patients underwent Decipher Biopsy testing between February 2015 and October 2019. Cumulative incidence curves for time to treatment (TTT) and time to failure (TTF) were constructed using Kaplan–Meier estimates. Multivariable Cox proportional hazard models were used to evaluate the independent association of high-risk Decipher scores with the conversion from active surveillance (AS) to radical therapy and treatment failure.

Results revealed that of the 855 men, 264 proceeded to AS (31%), and 454 (53%) received radical therapy. In men electing AS, after adjusting for age, PSA (prostate specific antigen), prostate volume, body mass index, and percent positive cores, a high-risk Decipher score was independently associated with shorter TTT. Similarly, in patients that underwent radical therapy, a high-risk Decipher score was independently associated with TTF. Furthermore, following removal of the prostate gland, high Decipher scores were associated with shorter time until recurrence of elevated PSA levels or when patients were put on anti-androgen therapy.

"Men with a high Decipher score who were placed on active surveillance had a shorter time before active treatment was needed," said first author Dr. Randy Vince, Jr., an oncology fellow at the University of Michigan. "We have long needed better tools to reduce the uncertainty of these initial treatment decisions."

Results of the Decipher clinical study were published in the July 20, 2021, online edition of the journal Prostate Cancer and Prostatic Diseases.

Related Links:

University of Michigan
Veracyte


New
Gold Supplier
Automated Immune Analyzer
UNION Immune Analyzer
New
Silver Supplier
COVID-19 NAb Test Solution
COVID-19 NAb Test Solution
New
Laboratory Management Software
HERA
New
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.